Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

Leukemia

Volumn 30, Issue 11, 2016, Pages 2179-2186

  Parker, H ^a   Rose Zerilli, M J J ^a   Larrayoz, M ^a   Clifford, R ^b   Edelmann, J ^c   Blakemore, S ^a   Gibson, J ^a   Wang, J ^d   Ljungstrom V ^e   Wojdacz, T K ^a   Chaplin, T ^d   Roghanian, A ^a   Davis, Z ^f   Parker, A ^f   Tausch, E ^c   Ntoufa, S ^g   Ramos, S ^b   Robbe, P ^b   Alsolami, R ^b   Steele, A J ^a   Packham, G ^a   Rodriguez Vicente A E ^h   Brown, L ^a   McNicholl, F ⁱ   Forconi, F ^a   Pettitt, A ^j   Hillmen, P ^k   Dyer, M ^l   Cragg, M S ^a   Chelala, C ^d   Oakes, C C ^m   Rosenquist, R ^e   Stamatopoulos, K ^g   Stilgenbauer, S ^c   Knight, S ^b   Schuh, A ^b   Oscier, D G ^a,f   Strefford, J C ^a   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^g INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^h CSIC   (Spain)

ⁱ ALTNAGELVIN HOSPITAL   (United Kingdom)

^j ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; HISTONE METHYLTRANSFERASE; MESSENGER RNA; PROTEIN P53; HISTONE LYSINE METHYLTRANSFERASE; SET2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE LOSS; GENE MUTATION; GENOMICS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SETD2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; WILD TYPE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; MORTALITY; MULTICENTER STUDY; MUTATION; PROGNOSIS; SURVIVAL RATE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENES, TUMOR SUPPRESSOR; GENOMICS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84973622859     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.134     Document Type: Article

References (44)

1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
2. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 21: 360-363.
3. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013; 125: 659-669.
4. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
5. Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014; 46: 287-293.
6. Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra RM et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 2010; 70: 4287-4291.
7. Pfister SX, Ahrabi S, Zalmas LP, Sarkar S, Aymard F, Bachrati CZ et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep 2014; 7: 2006-2018.
8. Carvalho S, Vítor AC, Sridhara SC, Martins FB, Raposo AC, Desterro JM et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife 2014, e02482.
9. Kanu N, Grönroos E, Martinez P, Burrell RA, YiGoh X, Bartkova J et al. SETD2 loss-offunction promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 2015; 34: 5699-5708.
10. Guièze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 2015; 126: 445-453.
11. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
12. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
13. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010; 95: 1705-1712.
14. Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One 2013; 8: e83244.
15. Parker H, Rose-Zerilli M, Parker A, Chaplin T, Chen X, Wade R et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 489-497.
16. Rose-Zerilli M, Forster J, Parker H, Parker A, Rodriguez A, Chaplin T et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia, data from the UK LRF CLL4 trial. Haematologica 2014; 99: 736-742.
17. Edelmann J, Saub J, Ibach S, Holzmann K, Tausch E, Bloehdorn J et al. High resolution genomic profiling of primary "ultra high risk" and refractory chronic lymphocytic leukemia: results from the CLL2O Trial. Blood (ASH Annual Meeting Abstracts) 2014; 120: 3288.
18. Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T et al. Highresolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012; 120: 4783-4794.
19. Knight SJ, Yau C, Clifford R, Timbs AT, Sadighi Akha E, Dréau HM et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pretreatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 2012; 26: 1564-1575.
20. Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 2014; 123: 1021-1031.
21. Parry M, Rose-Zerilli MJJ, Ljungström V, Gibson J, Wang J, Walewska R et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res 2015; 21: 4174-4183.
22. Robbe P, Clifford R, Timbs A, Burns A, Titsias M, Cabes M et al. Comprehensive Genome-wide Analysis of CLL Samples from UK 1st Line and Relapsed/Refractory. Clinical Trials. EHA Annual Meeting Abstracts, 2013:EHA18ABSSUB-4559.
23. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525-530.
24. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA 2008; 105: 17050-17054.
25. Ouillette P, Fossum S, Parkin B, Ding L, Bockenstedt P, Al-Zoubi A et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res 2010; 16: 835-847.
26. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
27. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
28. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526: 519-524.
29. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotech 2012; 30: 413-421.
30. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
31. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 2008; 27: 406-420.
32. Yoh SM, Lucas JS, Jones KA. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYP/Setd2-mediated histone H3K36 methylation. Gene Dev 2008; 22: 3422-3434.
33. Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012; 13: 115-126.
34. Li F, Mao G, Tong D, Huang J, Gu L, Yang W et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutS. Cell 2013; 153: 590-600.
35. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet 2009; 41: 376-381.
36. Sun XJ, Wei J, Wu XY, Hu M, Wang L, Wang HH et al. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem 2005; 280: 35261-35271.
37. Huether R, Dong L, Chen X, Wu G, Parker M, Wei L et al. The landscape of somatic mutations in epigenetic regulators across 1, 000 paediatric cancer genomes. Nat Commun 2014; 3: 3630.
38. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014; 5: 3469.
39. Lee WP, Stromberg MP, Ward A, Stewart C, Garrison EP, Marth GT. MOSAIK: A hash-based algorithm for accurate next-generation sequencing short-read mapping. PLoS One 2014; 9: e90581.
40. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013; 499: 214-218.
41. Kulis M, Heath S, Bibikova M, Queirós AC, Navarro A, Clot G et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44: 1236-1242.
42. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al. Oncomine 3. 0: genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles. Neoplasia 2007; 9: 166-180.
43. Xie P, Tian C, An L, Nie J, Lu K, Xing G et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 2008; 20: 1671-1678.
44. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 2014; 46: 939-943.